In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AltheRx Pharmaceuticals Inc.

Division of Velicept Therapeutics Inc.
www.altherx.com

Latest From AltheRx Pharmaceuticals Inc.

Start-Up Execs On The Move, June 2013

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Recent Financings Of Private Companies, June 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device

Start-Up Previews

This Month's Profile Group: VC-Backed GI Start-Ups See Opportunity In IBS features profiles of Altheus, AltheRx, Ardelyx and Second Genome. Plus these Start-Ups Across Health Care: InfraScan, PlaqueTec, Prosonix and Veracyte.

AltheRx Pharmaceuticals Inc.

AltheRx Pharmaceuticals Inc. acquired its lead compound, solabegron, from GlaxoSmithKline in March 2011. Solabegron relaxes smooth muscles by stimulating beta-3 adrenoceptors, a novel mechanism compared with currently available treatments for overactive bladder and irritable bowel syndrome, the first two indications that AltheRx is targeting.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Velicept Therapeutics Inc.
  • Senior Management
  • Jim Bennethum, CEO
    Eliot H Ohlstein, PhD, Head, R&D & CSO
  • Contact Info
  • AltheRx Pharmaceuticals Inc.
    Phone: (484) 395-2430
    490 Lapp Rd.
    Malvern, PA 19355
    USA
UsernamePublicRestriction

Register